Delivery Order 36F79718D0566-36C26124N0494
Award Date 3/13/24
Potential Completion Date 4/13/24
Potential Value $11K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a pharmaceutical manufacturer, for QALSODY (TOFERSEN) - EMERGENCY PHARMACY. The $21,738.30 firm-fixed-price order was placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract, with no set-aside applied. The order will be performed in Cambridge, MA and is set to be completed by May 30, 2024. Biogen also holds a...
- This federal contract award is for the delivery of QALSODY (TOFERSEN) 6.7MG SOLN (2 VIALS) NDC: 64406-0109-01 pharmaceutical product to the Department of Veterans Affairs (VA). The contract was awarded to Biogen U.S. Corporation, a subsidiary of Biogen Idec Incorporated, a biotechnology company focused on developing therapies for neurological diseases. The contract is a firm-fixed-price delivery order valued at $21,738.30, awarded against Biogen's Pharmaceuticals and Drugs General Services...
- This federal contract award to Biogen U.S. Corporation is for the delivery of the pharmaceutical product QALSODY (tofersen) to the U.S. Department of Veterans Affairs (VA). The $21,738.30 firm fixed price delivery order is placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract. The contract has no set-aside designation, indicating Biogen competed against other vendors to secure this award. Biogen U.S. Corporation is a subsidiary of Biogen Idec Incorporated that focuses on...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide...
- This contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a biotechnology company focused on developing therapies for neurological diseases. It is a delivery order against Biogen's Pharmaceuticals and Drugs GSA Schedule contract, with a firm-fixed-price of $10,869.15. The contract is for the pharmaceutical product QALSODY (TOFERSEN), which is likely used to treat neurological conditions in veterans. This order was placed by...
- This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 (VISN 21) to Genzyme Corporation, doing business as Sanofi Genzyme, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The $89,094.00 order is for the delivery of various specialty pharmaceutical products, including Eliglustat (Cerdelga), Lemtrada, and Caprelsa (vandetanib), to support treatment programs for veterans. Genzyme...
- The Department of Veterans Affairs Veterans Health Administration awarded a $652,376 delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order calls for the delivery of VALBENAZINE 80MG capsules to the Hines VA Medical Center in Illinois. The one-week period of performance from November 3 to November 10, 2020 indicates this was likely an urgent order to treat veterans for a condition addressed by the medication. Neurocrine...
- This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $265,045.04 firm fixed price delivery order to Genzyme Corporation, doing business under its Genzyme Therapeutics Division, for eliglustat medication. The period of performance is from October 1, 2020 to September 30, 2021. The delivery order was awarded against Genzyme Corporation's Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $17,830.87 delivery order to Genzyme Corporation, Sanofi Genzyme division, for eliglustat for the Puget Sound VA pharmacy. The contract was issued against the Pharmaceuticals and Drugs Federal Supply Schedule, known as FSS-61-IB, with a firm fixed price and completion date of November 1, 2019. The delivery order was not subject to any set-aside designations and will provide the...